These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29860423)

  • 41. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
    Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
    Jeon J; Kim W; Jang J; Isacson O; Seo H
    Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
    Martire A; Pepponi R; Domenici MR; Ferrante A; Chiodi V; Popoli P
    J Neurochem; 2013 Apr; 125(2):225-35. PubMed ID: 23363456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model.
    Dargaei Z; Bang JY; Mahadevan V; Khademullah CS; Bedard S; Parfitt GM; Kim JC; Woodin MA
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1618-E1626. PubMed ID: 29382760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice.
    Simmons DA; Rex CS; Palmer L; Pandyarajan V; Fedulov V; Gall CM; Lynch G
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4906-11. PubMed ID: 19264961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antidepressants for neuroprotection in Huntington's disease: A review.
    Jamwal S; Kumar P
    Eur J Pharmacol; 2015 Dec; 769():33-42. PubMed ID: 26511378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is Huntingtin Dispensable in the Adult Brain?
    Liu JP; Zeitlin SO
    J Huntingtons Dis; 2017; 6(1):1-17. PubMed ID: 28339401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways.
    Moily NS; Ormsby AR; Stojilovic A; Ramdzan YM; Diesch J; Hannan RD; Zajac MS; Hannan AJ; Oshlack A; Hatters DM
    Mol Cell Neurosci; 2017 Sep; 83():103-112. PubMed ID: 28743452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
    Hannan AJ; Ransome MI
    J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
    Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
    Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computational insights into missense mutations in HTT gene causing Huntington's disease and its interactome networks.
    Khan MQ; Mubeen H; Khan ZQ; Masood A; Zafar A; Wattoo JI; Nisa AU
    Ir J Med Sci; 2023 Jun; 192(3):1435-1445. PubMed ID: 35829908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's disease.
    Griffioen KJ; Wan R; Brown TR; Okun E; Camandola S; Mughal MR; Phillips TM; Mattson MP
    Neurobiol Aging; 2012 Jul; 33(7):1481.e1-5. PubMed ID: 22209255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease.
    Du Z; Chazalon M; Bestaven E; Leste-Lasserre T; Baufreton J; Cazalets JR; Cho YH; Garret M
    Neuroscience; 2016 Aug; 329():363-79. PubMed ID: 27217211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laquinimod treatment in the R6/2 mouse model.
    Ellrichmann G; Blusch A; Fatoba O; Brunner J; Reick C; Hayardeny L; Hayden M; Sehr D; Winklhofer KF; Saft C; Gold R
    Sci Rep; 2017 Jul; 7(1):4947. PubMed ID: 28694434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.